Announcement • 6h
Medios AG (XTRA:ILM1) agreed to acquire 74% stake in Caesar & Loretz GmbH. Medios AG (XTRA:ILM1) agreed to acquire 74% stake in Caesar & Loretz GmbH on August 11, 2026.
The transaction is subject to antitrust regulations. Caesar & Loretz is to continue to operate as an independent company under its own brand and will be led by Asiye Dogan. Upon the closing of the transaction, Ulrich von der Linde will step down from management. The company employs approximately 240 people at its operational GMP-certified sites in Hilden and Bonn. Announcement • Jul 01
Medios AG Closes the Facility of Its Wholly Owned Subsidiary, Medios Solutions Aschaffenburg GmbH Medios AG is closing the facility of its wholly owned subsidiary, Medios Solutions Aschaffenburg GmbH, and consolidated patient-specific manufacturing at the remaining locations in its Germany-wide network. Production had already been relocated, and supplies to pharmacies and hospitals are guaranteed. Aschaffenburg most recently accounted for approximately 10% of the production volume of the Medios Group’s German manufacturing facilities. The measure affects 32 employees, for whom Medios is seeking to provide fair compensation. The business of patient-specific formulations is under sustained margin pressure – particularly due to price regulatory adjustments – which the company is now countering with measures to increase efficiency. In Germany, Medios operates up until now a network of six GMP manufacturing facilities for patient-specific therapies (GMP stands for “Good Manufacturing Practice,” which entails mandatory production standards and validated quality management). The Aschaffenburg site had recently been operating at below-average profitability amid declining capacity utilization. Against this backdrop, continued economic operation was no longer feasible. Structural renovation work currently required at the site has accelerated the implementation of this decision. The site closure is part of the company’s Operational Excellence Program, which aims to sustainably strengthen profitability. Announcement • Apr 30
Medios AG, Annual General Meeting, Jun 10, 2026 Medios AG, Annual General Meeting, Jun 10, 2026, at 10:00 W. Europe Standard Time. Announcement • Apr 15
Medios AG, Annual General Meeting, May 27, 2025 Medios AG, Annual General Meeting, May 27, 2025, at 10:00 W. Europe Standard Time. Reported Earnings • Nov 14
Third quarter 2024 earnings released: EPS: €0.16 (vs €0.30 in 3Q 2023) Third quarter 2024 results: EPS: €0.16 (down from €0.30 in 3Q 2023). Revenue: €495.0m (up 1.0% from 3Q 2023). Net income: €4.03m (down 43% from 3Q 2023). Profit margin: 0.8% (down from 1.4% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 14
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Second quarter 2024 results: EPS: €0.10 (down from €0.19 in 2Q 2023). Revenue: €452.6m (up 7.2% from 2Q 2023). Net income: €2.42m (down 46% from 2Q 2023). Profit margin: 0.5% (down from 1.1% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.9%. Earnings per share (EPS) also missed analyst estimates by 44%. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings. New Risk • Jun 20
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company. Price Target Changed • Jun 09
Price target decreased by 12% to €32.40 Down from €37.00, the current price target is an average from 5 analysts. New target price is 95% above last closing price of €16.58. Stock is down 5.8% over the past year. The company is forecast to post earnings per share of €1.05 for next year compared to €0.79 last year. Announcement • Jun 08
Medios AG (XTRA:ILM1) acquired Ceban B.V. from Bencis Capital Partners B.V. Medios AG (XTRA:ILM1) agreed to acquire Ceban B.V. from Bencis Capital Partners B.V. for €259 million on March 18, 2024. The purchase price for the transaction includes a cash component of €235.3 million and 1.7 million new Medios shares valued approx. €23.9 million. The newly issued shares will be subject to a hard lock-up period of 24 months. The purchase price is financed by Medios from existing cash and an already committed credit facility. The 1.7 million new shares will be issued out of authorized capital against contributions in kind. Ceban had a preliminary revenue of €160 million in 2023. The preliminary EBITDA-adjusted amounts to €29 million in 2023. Ceban will continue to operate under its own brand names. Ceban’s strong and experienced management team has committed to remain fully involved to further drive growth in already existing markets and in new geographies within Europe. The completion of the transaction is subject to the fulfilment of customary closing conditions. The closing of the transaction is expected for the second quarter of 2024. The transaction has attractive multiple and immediately accretive to EBITDA pre and EBITDA pre margin.Jefferies LLC acted as financial advisor to Ceban. Dirk Besse and Sebastian Schwalme of Morrison & Foerster LLP acted as legal advisors for Medios AG. Danielle du Bois-Buné, Bastiaan van Rath, Hein van den Bos, Alexander Fortuin, Matthijs Dols, Maria Benbrahim, Mariëtte Vis, Chantal van Dam, Robert Masman, Tom van Duuren, Michael Schlitt, Susanne Ries, Sebastian Biller, Karolin Hiller, Fabien Roy, Falk Schöning of Hogan Lovells International Llp acted as sell-side legal advisor to Bencis Capital Partners B.V.Medios AG (XTRA:ILM1) completed the acquisition of Ceban B.V. from Bencis Capital Partners B.V. on June 6, 2024. The conditions required for the closing of the transaction were fully met. Ceban B.V. will be included in the scope of consolidation of Medios AG as of June 1, 2024. New Risk • Jun 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Reported Earnings • May 08
First quarter 2024 earnings released: EPS: €0.17 (vs €0.20 in 1Q 2023) First quarter 2024 results: EPS: €0.17 (down from €0.20 in 1Q 2023). Revenue: €457.4m (up 6.1% from 1Q 2023). Net income: €3.99m (down 17% from 1Q 2023). Profit margin: 0.9% (down from 1.1% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings. Price Target Changed • Mar 29
Price target decreased by 14% to €34.60 Down from €40.40, the current price target is an average from 5 analysts. New target price is 113% above last closing price of €16.24. Stock is down 18% over the past year. The company is forecast to post earnings per share of €1.33 for next year compared to €0.79 last year. Reported Earnings • Mar 29
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: €0.79 (up from €0.77 in FY 2022). Revenue: €1.79b (up 11% from FY 2022). Net income: €18.8m (up 2.6% from FY 2022). Profit margin: 1.1% (in line with FY 2022). Revenue missed analyst estimates by 1.5%. Earnings per share (EPS) also missed analyst estimates by 19%. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings. Announcement • Mar 20
Medios AG (XTRA:ILM1) agreed to acquire Ceban B.V. from Bencis Capital Partners B.V. for € 259 million. Medios AG (XTRA:ILM1) agreed to acquire Ceban B.V. from Bencis Capital Partners B.V. for € 259 million on March 18, 2024. The purchase price for the transaction includes a cash component of €235.3 million and 1.7 million new Medios shares valued approx. €23.9 million. The newly issued shares will be subject to a hard lock-up period of 24 months. The purchase price is financed by Medios from existing cash and an already committed credit facility. The 1.7 million new shares will be issued out of authorized capital against contributions in kind. Ceban had a preliminary revenue of €160 million in 2023. The preliminary EBITDA-adjusted amounts to €29 million in 2023. Ceban will continue to operate under its own brand names. Ceban’s strong and experienced management team has committed to remain fully involved to further drive growth in already existing markets and in new geographies within Europe. The completion of the transaction is subject to the fulfilment of customary closing conditions. The closing of the transaction is expected for the second quarter of 2024. Jefferies LLC acted as financial advisor to Ceban. Valuation Update With 7 Day Price Move • Mar 19
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to €17.72, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 13x in the Healthcare industry in Germany. Total loss to shareholders of 52% over the past three years. Announcement • Jan 06
Medios AG, Annual General Meeting, Jun 26, 2024 Medios AG, Annual General Meeting, Jun 26, 2024. Price Target Changed • Sep 29
Price target decreased by 19% to €34.25 Down from €42.40, the current price target is an average from 4 analysts. New target price is 129% above last closing price of €14.98. Stock is down 15% over the past year. The company is forecast to post earnings per share of €0.98 for next year compared to €0.77 last year. Announcement • Aug 15
Medios AG to Report Q3, 2023 Results on Nov 14, 2023 Medios AG announced that they will report Q3, 2023 results on Nov 14, 2023 Reported Earnings • Aug 15
Second quarter 2023 earnings released: EPS: €0.19 (vs €0.21 in 2Q 2022) Second quarter 2023 results: EPS: €0.19 (down from €0.21 in 2Q 2022). Revenue: €422.7m (up 5.8% from 2Q 2022). Net income: €4.44m (down 10% from 2Q 2022). Profit margin: 1.0% (down from 1.2% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Reported Earnings • May 12
First quarter 2023 earnings released: EPS: €0.20 (vs €0.21 in 1Q 2022) First quarter 2023 results: EPS: €0.20 (down from €0.21 in 1Q 2022). Revenue: €431.5m (up 9.8% from 1Q 2022). Net income: €4.83m (down 4.1% from 1Q 2022). Profit margin: 1.1% (down from 1.3% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 31
Full year 2022 earnings released: EPS: €0.77 (vs €0.37 in FY 2021) Full year 2022 results: EPS: €0.77 (up from €0.37 in FY 2021). Revenue: €1.61b (up 19% from FY 2021). Net income: €18.3m (up 148% from FY 2021). Profit margin: 1.1% (up from 0.5% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Price Target Changed • Mar 06
Price target decreased by 7.4% to €42.40 Down from €45.80, the current price target is an average from 5 analysts. New target price is 116% above last closing price of €19.60. Stock is down 23% over the past year. The company is forecast to post earnings per share of €0.78 for next year compared to €0.37 last year. Announcement • Dec 10
Medios AG to Report First Half, 2023 Results on Aug 14, 2023 Medios AG announced that they will report first half, 2023 results on Aug 14, 2023 Price Target Changed • Nov 17
Price target decreased to €45.80 Down from €50.80, the current price target is an average from 5 analysts. New target price is 163% above last closing price of €17.42. Stock is down 54% over the past year. The company is forecast to post earnings per share of €0.82 for next year compared to €0.37 last year. Price Target Changed • Nov 11
Price target decreased to €45.80 Down from €52.40, the current price target is an average from 5 analysts. New target price is 137% above last closing price of €19.32. Stock is down 52% over the past year. The company is forecast to post earnings per share of €0.82 for next year compared to €0.37 last year. Valuation Update With 7 Day Price Move • Sep 20
Investor sentiment deteriorated over the past week After last week's 16% share price decline to €21.85, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 13x in the Healthcare industry in Germany. Total returns to shareholders of 15% over the past three years. Reported Earnings • Aug 17
Second quarter 2022 earnings released: EPS: €0.21 (vs €0.17 in 2Q 2021) Second quarter 2022 results: EPS: €0.21 (up from €0.17 in 2Q 2021). Revenue: €399.5m (up 25% from 2Q 2021). Net income: €4.93m (up 44% from 2Q 2021). Profit margin: 1.2% (up from 1.1% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 13%, compared to a 3.4% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings. Reported Earnings • May 14
First quarter 2022 earnings: EPS and revenues miss analyst expectations First quarter 2022 results: EPS: €0.21 (up from €0.15 in 1Q 2021). Revenue: €393.1m (up 24% from 1Q 2021). Net income: €5.04m (up 77% from 1Q 2021). Profit margin: 1.3% (up from 0.9% in 1Q 2021). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 1.2%. Earnings per share (EPS) also missed analyst estimates by 4.5%. Over the next year, revenue is forecast to grow 16%, compared to a 5.7% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 15% per year, which means it is well ahead of earnings. Reported Earnings • Mar 30
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2021 results: EPS: €0.37. Revenue: €1.36b (up 117% from FY 2020). Net income: €7.40m (up 22% from FY 2020). Profit margin: 0.5% (down from 1.0% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.7%. Earnings per share (EPS) missed analyst estimates by 35%. Over the next year, revenue is forecast to grow 18%, compared to a 4.4% growth forecast for the industry in Germany. Price Target Changed • Mar 08
Price target decreased to €54.80 Down from €59.00, the current price target is an average from 5 analysts. New target price is 114% above last closing price of €25.55. Stock is down 26% over the past year. The company is forecast to post earnings per share of €0.57 for next year compared to €0.39 last year. Valuation Update With 7 Day Price Move • Mar 08
Investor sentiment deteriorated over the past week After last week's 18% share price decline to €25.55, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 16x in the Healthcare industry in Germany. Total returns to shareholders of 69% over the past three years. Price Target Changed • Nov 13
Price target increased to €51.75 Up from €48.00, the current price target is an average from 4 analysts. New target price is 30% above last closing price of €39.95. Stock is up 33% over the past year. The company is forecast to post earnings per share of €0.61 for next year compared to €0.39 last year. Reported Earnings • Nov 10
Third quarter 2021 earnings released: EPS €0.18 (vs €0.07 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €354.1m (up 121% from 3Q 2020). Net income: €3.62m (up 229% from 3Q 2020). Profit margin: 1.0% (up from 0.7% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Aug 13
Second quarter 2021 earnings released: EPS €0.17 (vs €0.06 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: €319.3m (up 146% from 2Q 2020). Net income: €3.43m (up 300% from 2Q 2020). Profit margin: 1.1% (up from 0.7% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • May 14
First quarter 2021 earnings released: EPS €0.15 (vs €0.15 in 1Q 2020) The company reported a solid first quarter result with improved earnings and revenues, although profit margins were weaker. First quarter 2021 results: Revenue: €316.0m (up 94% from 1Q 2020). Net income: €2.84m (up 23% from 1Q 2020). Profit margin: 0.9% (down from 1.4% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 18% per year and the company’s share price has also increased by 18% per year. Reported Earnings • Apr 02
Full year 2020 earnings released: EPS €0.39 (vs €0.67 in FY 2019) The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: €627.4m (up 21% from FY 2019). Net income: €6.06m (down 38% from FY 2019). Profit margin: 1.0% (down from 1.9% in FY 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 23% per year whereas the company’s share price has increased by 20% per year. Is New 90 Day High Low • Mar 06
New 90-day low: €35.50 The company is down 5.0% from its price of €37.30 on 04 December 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Healthcare industry, which is down 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €19.99 per share. Is New 90 Day High Low • Jan 06
New 90-day high: €38.50 The company is up 28% from its price of €30.00 on 08 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €26.57 per share. Price Target Changed • Dec 01
Price target raised to €40.33 Up from €37.67, the current price target is an average from 3 analysts. The new target price is 8.7% above the current share price of €37.10. As of last close, the stock is up 51% over the past year. Is New 90 Day High Low • Nov 27
New 90-day high: €35.50 The company is up 36% from its price of €26.10 on 28 August 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €92.05 per share. Valuation Update With 7 Day Price Move • Nov 27
Market bids up stock over the past week After last week's 17% share price gain to €35.50, the stock is trading at a trailing P/E ratio of 72.4x, up from the previous P/E ratio of 61.8x. This compares to an average P/E of 18x in the Healthcare industry in Germany. Total returns to shareholders over the past three years are 129%. Reported Earnings • Nov 25
Third quarter 2020 earnings released: EPS €0.07 The company reported a soft third quarter result with weaker earnings and profit margins, although revenues were improved. Third quarter 2020 results: Revenue: €160.1m (up 11% from 3Q 2019). Net income: €1.10m (down 62% from 3Q 2019). Profit margin: 0.7% (down from 2.0% in 3Q 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Nov 05
Market bids up stock over the past week After last week's 21% share price gain to €29.00, the stock is trading at a trailing P/E ratio of 47.8x, up from the previous P/E ratio of 39.6x. This compares to an average P/E of 17x in the Healthcare industry in Germany. Total returns to shareholders over the past three years are 92%. Is New 90 Day High Low • Oct 26
New 90-day low: €25.20 The company is down 32% from its price of €36.90 on 28 July 2020. The German market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is down 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €49.17 per share. Announcement • Jul 31
Medios AG (XTRA:ILM1) completed the acquisition of Kölsche Blister GmbH. Medios AG (XTRA:ILM1) entered into a purchase agreement to acquire Kölsche Blister GmbH for €3 million on March 19, 2020. As per terms of transaction, consideration will be paid half in cash and shares respectively. Medios AG will issue 0.064571 million shares. Medios AG raised loan of 62.5 from Deutsche Bank AG to finance the further acquisition and finance growth. For the year ended December 31, 2029, Kölsche Blister GmbH reported revenue of €14.3 million
Medios AG (XTRA:ILM1) completed the acquisition of Kölsche Blister GmbH in the first quarter of 2020. Announcement • Jul 10
Medios AG to Report Q3, 2020 Results on Nov 12, 2020 Medios AG announced that they will report Q3, 2020 results on Nov 12, 2020 
